Dosage du baclofène dans le plasma en chromatographie phase liquide couplée à de la spectrométrie de masse en tandem : à propos d’un cas de surdosage

Labat, Laurence; Goncalves, Antonio; Cleophax, Cédric; Mégarbane, Bruno; Declèves, Xavier

doi:10.1016/j.toxac.2016.04.001

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma samples collected from sublingual and retro‐orbital sinus were used to determine the concentrations of baclofen by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) after protein precipitation, as previously described 49 . Plasma samples were collected 30, 60, and 180 minutes after RS(±)‐Baclofen (2mg/kg) injection in dependent rats.…”

Section: Methodsmentioning

confidence: 99%

Is R(+)‐Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side

et al. 2020

Self Cite

View full text Add to dashboard Cite

For several decades, studies conducted to evaluate the efficacy of RS(±)‐Baclofen in the treatment of alcohol dependence yielded contrasting results. Human and animal studies recently questioned the use of the racemic drug in patients since a potential important role of the different enantiomers has been revealed with an efficacy thought to reside with the active R(+)‐enantiomer. Here we conducted experiments in the postdependent rat model of alcohol dependence to compare the efficacy of R(+)‐Baclofen or S(−)‐Baclofen to that of RS(±)‐Baclofen on ethanol intake, seeking, and relapse. R(+)‐Baclofen was more effective than RS(±)‐Baclofen in reducing ethanol intake and seeking during acute withdrawal and during relapse after abstinence. We also used an original population approach in order to identify drug responders. We found a significant proportion of responders to S(−)‐Baclofen and RS(±)‐Baclofen, displaying an increase in ethanol intake, and this increasing effect on alcohol intake was not seen in the R(+)‐Baclofen group. At an intermediate dose of R(+)‐Baclofen, devoid of any motor side effects, we identified a very large proportion of responders (75%) with a large decrease in ethanol intake (90% decrease). Finally, the response to RS(±)‐Baclofen on ethanol intake was correlated to plasma level of Baclofen. R(+)‐Baclofen and RS(±)‐Baclofen were effective in reducing sucrose intake. Our study has important clinical implication since it suggests that the wide variability in the therapeutic responses of patients to RS(±)‐Baclofen may come from the sensitivity to the R(+)‐Baclofen but also to the one of the S(−)‐Baclofen that can promote an increase in ethanol intake.

show abstract

Section: Methodsmentioning

confidence: 99%

Is R(+)‐Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The assays of baclofen were mainly performed by liquid chromatography coupled to tandem mass spectrometry after protein precipitation. This assay method is validated in plasma according to European Medicines Agency (EMA) standards with a linear response for concentrations ranged between 10 and 2000 μg/L (r2> 0.999) and precisions and accuracies below 11.5% [9]. Some laboratories used other methods for analysis.…”

Section: Methodsmentioning

confidence: 99%

Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function?

Brunet

Léger

Billat

et al. 2020

Anaesthesia Critical Care & Pain Medicine

View full text Add to dashboard Cite

Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning

Ghannoum¹,

Berling²,

Lavergne³

et al. 2021

Kidney International

View full text Add to dashboard Cite

Dosage du baclofène dans le plasma en chromatographie phase liquide couplée à de la spectrométrie de masse en tandem : à propos d’un cas de surdosage

Cited by 5 publications

References 17 publications

Is R(+)‐Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side

Is R(+)‐Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side

Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function?

Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning

Contact Info

Product

Resources

About